GSTM2 and rectal cancer: To evaluate selected aberrant DNA methylation of GFRA1 and GSTM2 as potential molecular biomarkers, ROC curve data were obtained by plotting the rate of sensitivity versus 100-specificity with dataset GSE48684 containing colon cancers and rectal cancers [33], which is available from the Gene Expression Omnibus (GEO) website.